Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6

Benzinga Newsdesk www.benzinga.com Neutral 70.8%